Spots Global Cancer Trial Database for Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia

Official Title: Target: Identification for High Risk Childhood AML Based on Genome-Wide Analysis

Study ID: NCT01076569

Conditions

Childhood Acute Basophilic Leukemia

Childhood Acute Eosinophilic Leukemia

Childhood Acute Erythroleukemia (M6)

Childhood Acute Megakaryocytic Leukemia (M7)

Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)

Childhood Acute Monoblastic Leukemia (M5a)

Childhood Acute Monocytic Leukemia (M5b)

Childhood Acute Myeloblastic Leukemia With Maturation (M2)

Childhood Acute Myeloblastic Leukemia Without Maturation (M1)

Childhood Acute Myelomonocytic Leukemia (M4)

Recurrent Childhood Acute Myeloid Leukemia

Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

Interventions

laboratory biomarker analysis

Study Description

Brief Summary: This pilot research trial studies biomarkers in bone marrow samples from pediatric patients with high risk acute myeloid leukemia. Studying samples of bone marrow from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.

Detailed Description: PRIMARY OBJECTIVES: I. To provide a detailed, molecular map of pediatric high risk acute myeloid leukemia (AML). II. To identify mutations, expression profile, gene copy number, loss of heterozygosity (LOH) status and genomic methylation patterns in order to identify novel changes associated with pediatric AML. III. To generate fibroblast cell lines in order to obtain germline nucleic acids from marrow specimens from AML patients with induction failure. IV. To identify genomic alterations contributing to induction failure in childhood AML. OUTLINE: Banked bone marrow samples from diagnosis and remission are used to develop a detailed molecular map of pediatric high-risk acute myeloid leukemia. Analysis includes genome single nucleotide polymorphism (SNP) genotyping, expression, and methylation profiling.